1. Home
  2. YDKG vs AVXL Comparison

YDKG vs AVXL Comparison

Compare YDKG & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YDKG
  • AVXL
  • Stock Information
  • Founded
  • YDKG 2005
  • AVXL 2004
  • Country
  • YDKG China
  • AVXL United States
  • Employees
  • YDKG N/A
  • AVXL N/A
  • Industry
  • YDKG Advertising
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • YDKG Consumer Discretionary
  • AVXL Health Care
  • Exchange
  • YDKG Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • YDKG 715.1M
  • AVXL 635.6M
  • IPO Year
  • YDKG N/A
  • AVXL N/A
  • Fundamental
  • Price
  • YDKG $1.55
  • AVXL $3.46
  • Analyst Decision
  • YDKG
  • AVXL Strong Buy
  • Analyst Count
  • YDKG 0
  • AVXL 3
  • Target Price
  • YDKG N/A
  • AVXL $33.00
  • AVG Volume (30 Days)
  • YDKG 2.5M
  • AVXL 2.9M
  • Earning Date
  • YDKG 11-17-2025
  • AVXL 12-22-2025
  • Dividend Yield
  • YDKG N/A
  • AVXL N/A
  • EPS Growth
  • YDKG N/A
  • AVXL N/A
  • EPS
  • YDKG N/A
  • AVXL N/A
  • Revenue
  • YDKG $13,107,000.00
  • AVXL N/A
  • Revenue This Year
  • YDKG N/A
  • AVXL N/A
  • Revenue Next Year
  • YDKG N/A
  • AVXL N/A
  • P/E Ratio
  • YDKG N/A
  • AVXL N/A
  • Revenue Growth
  • YDKG 2175.52
  • AVXL N/A
  • 52 Week Low
  • YDKG $1.65
  • AVXL $2.86
  • 52 Week High
  • YDKG $472.00
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • YDKG N/A
  • AVXL 14.11
  • Support Level
  • YDKG N/A
  • AVXL $2.86
  • Resistance Level
  • YDKG N/A
  • AVXL $7.25
  • Average True Range (ATR)
  • YDKG 0.00
  • AVXL 0.66
  • MACD
  • YDKG 0.00
  • AVXL -0.40
  • Stochastic Oscillator
  • YDKG 0.00
  • AVXL 13.66

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: